A year after landing a $37 million series A to support its mission of addressing the most desperate of rare diseases, Rallybio LLC linked up with Exscientia Ltd. to form RE Ventures, a joint venture designed to accelerate the discovery of small-molecule drug therapies targeting rare disease indications.